NCT06958692

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Adult Patients With Major Depressive Disorder

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 388 (estimated)
• Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive disorder.

Conditions

• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Dextromethorphan and Bupropion Sustained-Release Tablets	Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
DRUG	Placebo	Oral placebo tablets, taken daily for 6 weeks.

Timeline

• Start date: 2025-04-11
• Primary completion: 2026-09-30
• Completion: 2026-12-30
• First posted: 2025-05-06
• Last updated: 2025-05-06

Locations

1 site across 1 country: China